| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1065: Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | Concentrate for solution for infusion |
| Reference number | 4659 |
| Indication | For treatment of untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| NICE guidance | |